1. Chen L, Li X, Chen M, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res 2020;116:1097–100. https://doi.org/10.1093/cvr/cvaa078; PMID: 32227090.
2. Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020;20:363–74. https://doi.org/10.1038/s41577-020-0311-8; PMID: 32346093.
3. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020;75:2950–73. https://doi.org/10.1016/j.jacc.2020.04.031; PMID: 32311448.
4. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020;395:497–506. https://doi.org/10.1001/jamacardio.2020.0950; PMID: 32211816.
5. Shi S, Qin M, Cai Y, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J 2020;41:2070–9. https://doi.org/10.1093/eurheartj/ehaa408; PMID: 32391877.